295 related articles for article (PubMed ID: 21256046)
21. Targeted therapies in metastatic esophageal cancer: advances over the past decade.
Mohamed A; El-Rayes B; Khuri FR; Saba NF
Crit Rev Oncol Hematol; 2014 Aug; 91(2):186-96. PubMed ID: 24582516
[TBL] [Abstract][Full Text] [Related]
22. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients.
Lieto E; Ferraraccio F; Orditura M; Castellano P; Mura AL; Pinto M; Zamboli A; De Vita F; Galizia G
Ann Surg Oncol; 2008 Jan; 15(1):69-79. PubMed ID: 17896140
[TBL] [Abstract][Full Text] [Related]
23. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
Garrido M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
[TBL] [Abstract][Full Text] [Related]
24. Current status of ramucirumab in gastroesophageal adenocarcinoma.
Elimova E; Lin Q; Song S; Ajani JA
Future Oncol; 2017 Aug; 13(18):1585-1592. PubMed ID: 28436242
[TBL] [Abstract][Full Text] [Related]
25. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
26. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
Wagner AD; Moehler M
Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098
[TBL] [Abstract][Full Text] [Related]
27. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.
Nakamura Y; Kawazoe A; Lordick F; Janjigian YY; Shitara K
Nat Rev Clin Oncol; 2021 Aug; 18(8):473-487. PubMed ID: 33790428
[TBL] [Abstract][Full Text] [Related]
28. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.
Sahin U; Schuler M; Richly H; Bauer S; Krilova A; Dechow T; Jerling M; Utsch M; Rohde C; Dhaene K; Huber C; Türeci Ö
Eur J Cancer; 2018 Sep; 100():17-26. PubMed ID: 29936063
[TBL] [Abstract][Full Text] [Related]
29. Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer.
Rohrberg KS; Skov BG; Lassen U; Christensen IJ; Høyer-Hansen G; Buysschaert I; Pappot H
Cancer Biomark; 2010; 7(3):141-51. PubMed ID: 21263190
[TBL] [Abstract][Full Text] [Related]
30. Preoperative and adjuvant therapies for upper gastrointestinal cancers.
Varadhachary G; Ajani JA
Expert Rev Anticancer Ther; 2005 Aug; 5(4):719-25. PubMed ID: 16111471
[TBL] [Abstract][Full Text] [Related]
31. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
Maron SB; Catenacci DVT
Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
[TBL] [Abstract][Full Text] [Related]
32. Optimal management of gastroesophageal junction cancer.
Greally M; Agarwal R; Ilson DH
Cancer; 2019 Jun; 125(12):1990-2001. PubMed ID: 30973648
[TBL] [Abstract][Full Text] [Related]
33. Update on metastatic gastric and esophageal cancers.
Shah MA
J Clin Oncol; 2015 Jun; 33(16):1760-9. PubMed ID: 25918288
[TBL] [Abstract][Full Text] [Related]
34. Ramucirumab: first global approval.
Poole RM; Vaidya A
Drugs; 2014 Jun; 74(9):1047-58. PubMed ID: 24916147
[TBL] [Abstract][Full Text] [Related]
35. Adenocarcinoma of the GEJ: gastric or oesophageal cancer?
Rüschoff J
Recent Results Cancer Res; 2012; 196():107-13. PubMed ID: 23129369
[TBL] [Abstract][Full Text] [Related]
36. Molecular mechanisms and targeting of colorectal cancer.
Vanhoefer U
Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
[TBL] [Abstract][Full Text] [Related]
37. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
[TBL] [Abstract][Full Text] [Related]
38. Targeted Treatment of Esophagogastric Cancer.
Kopp HG; Hofheinz RD
Oncol Res Treat; 2016; 39(12):788-794. PubMed ID: 27889780
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review.
Arnold D; Peinert S; Voigt W; Schmoll HJ
Oncologist; 2006 Jun; 11(6):602-11. PubMed ID: 16794239
[TBL] [Abstract][Full Text] [Related]
40. Molecular determinants in targeted therapy for esophageal adenocarcinoma.
Vallböhmer D; Peters JH; Kuramochi H; Oh D; Yang D; Shimizu D; DeMeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; Danenberg PV; DeMeester TR
Arch Surg; 2006 May; 141(5):476-81; discussion 481-2. PubMed ID: 16702519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
